(function(){var loadHandler=window['sl_{E3D701B7-9456-41DA-AA5D-ED55FDEB2C76}'];loadHandler&&loadHandler(6, '<div id="spr0_347edc92"><div id="spr1_347edc92" class="kern slide"><img id="img5_347edc92" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_347edc92" class="kern slide"><img id="img0_347edc92" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_347edc92" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_347edc92" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_347edc92" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_347edc92" style="left:657.715px;top:499.855px;"><img id="img2_347edc92" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_347edc92" style="left:25.093px;top:9.342px;"><div style="width:0px;"><span id="txt0_347edc92" data-width="593.468750" style="left:44.974px;top:5.086px;">Many High-Risk Canadian Patients Treated with</span></div><div style="width:0px;"><span id="txt1_347edc92" data-width="371.750000" style="left:155.544px;top:43.486px;">Statins Are Not at LDL-C Goal</span></div></div><div id="spr5_347edc92" style="left:-22.456px;top:115.149px;"><img id="img3_347edc92" src="data/img15.png" width="242" height="162" alt="" style="left:0.232px;top:-0.178px;"/></div><div id="spr6_347edc92" style="left:-22.456px;top:283.54px;"><img id="img4_347edc92" src="data/img16.png" width="242" height="162" alt="" style="left:0.232px;top:-0.178px;"/></div><div id="spr7_347edc92" style="left:179.557px;top:140.548px;"><div style="width:0px;"><span id="txt2_347edc92" class="relpos" data-width="59.050781" style="left:7.2px;top:4.715px;">DYSIS</span><span id="txt3_347edc92" class="relpos" style="left:7.195px;top:4.976px;">1</span></div><div style="width:0px;"><span id="txt4_347edc92" class="relpos" data-width="365.783203" style="left:7.2px;top:33.236px;">Canadian high-risk patients are NOT at LDL-C target</span><span id="txt5_347edc92" class="relpos" style="left:7.195px;top:34.512px;">1</span><span id="txt6_347edc92" class="relpos" style="left:7.19px;top:33.432px;">*</span><span id="txt7_347edc92" class="relpos" data-width="99.667969" style="left:7.185px;top:33.236px;"> (&lt; 2.0 mmo/L)</span></div><div style="width:0px;"><span id="txt8_347edc92" class="nokern relpos" style="left:7.2px;top:55.249px;"></span><span id="txt9_347edc92" class="relpos" data-width="361.804688" style="left:22.38px;top:54.882px;">88% of patients received a ‘potent’ statin with suboptimal dose</span></div><div style="width:0px;"><span id="txt10_347edc92" class="nokern relpos" style="left:7.2px;top:74.449px;"></span><span id="txt11_347edc92" class="relpos" data-width="320.210938" style="left:22.38px;top:74.082px;">14% of patients received additional lipid-lowering agent</span></div></div><div id="spr8_347edc92" style="left:179.557px;top:327.193px;"><div style="width:0px;"><span id="txt12_347edc92" class="relpos" data-width="92.882813" style="left:7.2px;top:4.715px;">DM-SCAN</span><span id="txt13_347edc92" class="relpos" style="left:7.195px;top:4.976px;">2</span></div><div style="width:0px;"><span id="txt14_347edc92" class="relpos" data-width="396.966797" style="left:7.2px;top:33.236px;">Canadian patients with diabetes are NOT at LDL-C target</span><span id="txt15_347edc92" class="relpos" data-width="8.208984" style="left:7.195px;top:33.432px;">† </span><span id="txt16_347edc92" class="relpos" data-width="100.924805" style="left:7.19px;top:33.236px;"> (≤ 2.0 mmo/L)</span></div><div style="width:0px;"><span id="txt17_347edc92" class="nokern relpos" style="left:7.2px;top:55.249px;"></span><span id="txt18_347edc92" class="relpos" data-width="268.414063" style="left:22.38px;top:54.882px;">82% of patients were on a lipid-lowering agent</span></div></div><div id="spr9_347edc92" style="left:66.526px;top:171.531px;"><div style="width:0px;"><span id="txt19_347edc92" data-width="25.539063" style="left:9.312px;top:4.901px;">45</span></div><div style="width:0px;"><span id="txt20_347edc92" style="left:34.812px;top:4.901px;">%</span></div></div><div id="spr10_347edc92" style="left:66.526px;top:343.762px;"><div style="width:0px;"><span id="txt21_347edc92" data-width="25.539063" style="left:9.312px;top:4.901px;">43</span></div><div style="width:0px;"><span id="txt22_347edc92" style="left:34.812px;top:4.901px;">%</span></div></div><div id="spr11_347edc92" style="left:16.455px;top:445.452px;"><div style="width:0px;"><span id="txt23_347edc92" class="nokern" data-width="566.917969" style="left:7.2px;top:4.179px;">*High risk = coronary artery disease, peripheral arterial disease, cerebrovascular disease, diabetes mellitus or Framingham 10-year risk score ≥20%.</span></div><div style="width:0px;"><span id="txt24_347edc92" class="nokern" data-width="207.282715" style="left:7.2px;top:16.779px;">DYSIS Study – 2,436 patients, 1913 high risk patients.</span></div><div style="width:0px;"><span id="txt25_347edc92" class="nokern relpos" style="left:7.2px;top:29.455px;">†</span><span id="txt26_347edc92" class="nokern relpos" data-width="37.580566" style="left:7.195px;top:29.379px;">N = 5,069</span></div></div><div id="spr12_347edc92" style="left:4.43px;top:506.2px;"><div style="width:0px;"><span id="txt27_347edc92" class="nokern" data-width="345.076172" style="left:7.2px;top:4.096px;">1. Goodman SG et al. on behalf of the DYSIS Canadian Investigators. Can J Cardiol. 2010;26:e330-e335.</span></div><div style="width:0px;"><span id="txt28_347edc92" class="nokern" data-width="297.043945" style="left:7.2px;top:14.896px;">2. Leiter LA et al. on behalf of the DM-SCAN investigators. Can J Diabetes. 2013;37:82-89.</span></div></div></div></div>');})();